semaglutide ckd approval FDA has approved Ozempic (semaglutide) to slow progression of chronic kidney disease in type 2 diabetes—first GLP‑1 under this indication, reducing risk by 24%. #glp_1 #GLP1 #CoreAgeRX #CoreAge #Core_Age_RX https://coreagerx.com Effects of Once-Weekly Semaglutide on

Alcohol can worsen gastrointestinal side effects and interfere with blood glucose regulation

Antioxidant glutathione (GSH) is found in high concentrations in many tissues within the human body and has been shown to play roles in mitigating oxidative stress and inflammation, maintaining redox balance, enhancing metabolic detoxification processes, and regulating immune function

I expect the GLP-1 receptor agonist, GIP and similar novel medications in the weight loss category to have that same outsized favorable impact overall

ineffective interventions delay meaningful health improvements

2021;10(14): e020734

Were in a good position of leveraging our portfolio to satisfy the needs of those consumers, Acevedo told Food Dive